In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

BioFocus and UK company Xention to develop cardiac drugs

Executive Summary

In a two-year agreement, BioFocus (bioinformatics) and newly formed UK company Xention Discovery (ion channel drug discovery) are looking to discover and develop candidates that interact with an ion channel target to treat atrial fibrillation, the most common type of cardiac arrhythmia.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
Deal Status
  • Final
Deal Type
  • Alliance
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register